草酸艾司西酞普兰对脑卒中后抑郁患者的疗效。
Efficacy of escitalopram oxalate for patients with post-stroke depression.
作者信息
Xu Ji-Hua, Jiang Peng
机构信息
Department of Neurolgy, Beijing ChaoYang Hospital, Capital Medical University, Beijing, China.
出版信息
Medicine (Baltimore). 2018 Apr;97(14):e0219. doi: 10.1097/MD.0000000000010219.
This retrospective study investigated the efficacy and safety of escitalopram oxalate (ESO) for the treatment of post-stroke depression (PSD).A total of 115 patients with PSD were included in this study. A total of 65 patients underwent ESO (Intervention group). A total of 50 patients received acupressure (Control group). The outcome measurements included Montgomery-Åsberg Depression Rating Scale (MADRS), Hamilton Anxiety Rating Scale (HAM-A), and Sheehan Disability Scale (SDS). In addition, we also recorded the adverse events in this study.At the end of 8-week treatment, ESO showed greater efficacy in depression, measured by MADRS (P < .01); anxiety, measured by HAM-A scale (P < .01); and disability, measured by SDS (P < .01), compared to acupressure. Additionally, there were not significant differences regarding adverse events between two groups (P > .05).The present results indicate that ESO can decrease symptoms of patients with PSD.
这项回顾性研究调查了草酸艾司西酞普兰（ESO）治疗卒中后抑郁（PSD）的疗效和安全性。本研究共纳入115例PSD患者。其中65例患者接受ESO治疗（干预组）。另外50例患者接受指压治疗（对照组）。疗效指标包括蒙哥马利-艾斯伯格抑郁量表（MADRS）、汉密尔顿焦虑量表（HAM-A）和希恩残疾量表（SDS）。此外，我们还记录了本研究中的不良事件。在8周治疗结束时，与指压治疗相比，ESO在通过MADRS评估的抑郁（P<0.01）、通过HAM-A量表评估的焦虑（P<0.01）以及通过SDS评估的残疾方面（P<0.01）均显示出更高的疗效。此外，两组之间在不良事件方面无显著差异（P>0.05）。目前的结果表明，ESO可减轻PSD患者的症状。
Zotero 插件